Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Nalmefene Injection For Opioid Overdose in ERs Concludes
Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
Details : Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Zurnai™ Auto-Injector for Opioid Overdose Treatment in Adults and Children
Details : Zurnai (nalmefene hydrochloride) Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : MMCAP Infuse
Deal Size : Undisclosed
Deal Type : Agreement
Purdue Pharma Enters Agreement for Low-Cost Opioid Use Disorder Treatment in Prisons
Details : The agreement provides low-cost buprenorphine and naloxone tablets to correctional facilities for opioid use disorder treatment.
Product Name : Suboxone-Generic
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Buprenorphine,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : MMCAP Infuse
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : The University of New Mexico
Deal Size : Undisclosed
Deal Type : Financing
Purdue Grants Funding for Research on Opioid Overdose Reversal with Nalmefene Injection
Details : The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.
Product Name : Nalmefene Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : The University of New Mexico
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Harm Reduction Therapeutics
Deal Size : $29.9 million
Deal Type : Financing
Details : The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid ov...
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Harm Reduction Therapeutics
Deal Size : $29.9 million
Deal Type : Financing
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : Harm Reduction Therapeutics
Deal Size : $17.5 million
Deal Type : Financing
Details : The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.
Product Name : RiVive
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : Harm Reduction Therapeutics
Deal Size : $17.5 million
Deal Type : Financing
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA recently approved ANDA for nalmefene hydrochloride Injection, an opioid antagonist indicated for reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in management of known or suspecte...
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA has approved ANDA for Nalmefene hydrochloride injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, induced by either natural or synthetic opioids, and in management of known suspected opioid overdose.
Product Name : Zurnai
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable